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Abstract: Clinical features of asthma patients with bronchiolar obstruction (type II
asthma) were studied in relation to the proportion of neutrophils in bronchoalveolar
lavage (BAL) fluid. Of 13 subjects studied, 7 were accompanied with BAL
neutrophilia (53.5%) (BALn+) and 6 were without BAL neutrophilia (3.5%) (BALn-).
1. The mean age was higher in BALn- (66.0 years) than in BALn+ patients (55.0
years). 2. Bronchial reactivity to methacholine was slightly higher in BALn- patients
than in those with BALn+. 3. The value of FEV1.0% was significantly lower in
BALn+ patints than in those with BALn- (p<o.on. 4. The proportion of BAL
lymphocytes was signicantly more decreased in BALn+ patients compared to the
proportion in those with BALn- (p<o.oon. 5. the values of serum IgG, IgA, and IgM
were not significantly different between BALn+ and BALn- patients, however, the
value of IgG was more decreased in BALn+ patients than in those with BALn-.
These results suggest that two kinds of type II asthma; one is with BAL
neutrophilia related to suppressed immunity, and another is without BAL neutrophilia
in part due to aging.
Key words: Bronchial asthma, Bronchiolar obstruction, BAL neutrophilia, Suppressed
immunity, Aging
Introduction
The major pathophysiological changes in
the airways of bronchial asthma are bron-
choconstriction, mucus hypersecretion, edema
of mucous membrane, and bronchiolar ob-
struction. Our previous studies have shown
that asthma is classified into three funda-
mental types ; lao simple bronchoconstriction
type, lb. bronchoconstriction + hypersecretion
type, and II. bronchiolar obstruction type,
according to these changes III the au-
ways 1-5). Of three asthma types, type II
asthma (bronchiolar obstruction) is charac-
terized by increased number of neutrophils
and decreased lymphocyte count III
bronchoalveolar lavage (BAL) fluid 4. 5) ,
which are often observed in asthma patients
with long-term glucocorticoid therapy 6-8).
Airway inflammation, in which migration
2 Type II asthma without BAL neutrophilia
of lymphocytes, eosinophils, neutrophils, and
basophils into local allergic reaction sites is
observed in patients with asthma 9-12). It has
been suggested that activated T lymphocytes
and eosinophils play an important role as
inflammatory cells inducing asthmatic reac-
tion la 14). Furthermore, a role of neutrophils
in the airways of asthma has been noted m
recent years I~ 16) .
Increased number of BAL neutrophils may
be caused by suppression of local and / or
generalized humoral and cellular imm-
unity 7. 8). Thus, pathophysiology of type II
(bronchiolar obstruction) asthma is closely
related with BAL neutrophilia 4. 5). However,
our recent clinical observations have shown
that there are some type II asthma patients
without BAL neutrophilia.
In the present study, clinical features of
type II asthma without BAL neutrophilia
were analyzed, comparing to those of same
type with BAL neutrophilia, in relation to
patient age, bronchial hyperresponsiveness,
ventilatory function, and BAL lymphocyte
count.
Subjects and Methods
The subjects of this study were 13 asthma
patients with bronchiolar obstruction (type
II ). Of these, 7 were patients with BAL
neutrophilia (more than 10%) (BALn+), and
6 without BAL neutrophilia (BALn-). All
patients had a long-term systemic glucocor-
ticoid therapy for more than 2 years.
To evaluate type II asthma, classification
of asthma by clinical symptoms (clinial
diagnosis) 2. 4. 5) was applied, but not class-
ification by clinical findings and examina-
tions (score diagnosis) 3) •
Bronchial reactivity to methacholine was
measured by an Astograph (TCK 6100, Chest
Co) 17.18). Different concentrations of metha-
choline (49, 98, 195, 390, 781, 1563, 3125,
6250, 12500 and 25000 Itg/m!) were prepared
for bronchial challenge according to the
mthod used by Chai et aP9). The increase of
total respiratory resistance (Rrs) after
methacholine inhalation was measured by the
oscillation method~). A methacholine concen-
tration causing a significant increase in Rrs
was assessed as Cmin (minimum concentra-
tion). All medications were stopped 12 hours
prior to examination.
BAL was carried out in all patients accord-
ing to the methud previosly described when
they were symptom free 4-7), and informed
consent for this examination was obtained
from all study subjects.
Vantilatory function was carried out in all
subjects at attack-free stage, using a Box
Spiror 81 (Chest Co).
Serum 19E was measured by radioimm-
unosorbent test (RlST) and 19E antibodies
were estimated by radioallergosorbent test
(RAST).
Results
Table 1 shows characteristics of type II
asthma patients with and without BAL
neutrophilia. Mean age was higher in asthma
patients without BAL neutrophilia (BALn-)
than m those with BAL neutrophilia
(BALn+). In contrast, mean age at onset of
the disease was lower in BALn- patients than
in those with BALn+. The level of serum IgE
was not significantly different between two
asthma groups.
Bronchial reactivity to methacholine was
slightly higher in BALn- patients compared
to that in those with BALn+, as shown in
Fig. 1. However, this was not significant.
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Table 1. Characteristics of type II asthma
patients with and without BAL
neutrophilia
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Fig. 1. Bronchial reactivity to methacholine in
type II asthma with (BALn+) and
without BAL neutrophilia (BALn-)
Figure 2 demonstrates comparison III the
value of FEV 1.0% between two asthma
groups. The value of FEV 1.0% was signifi-
cantly lower in BALn+ patients than in those
with BALn- (p<O.Ol).
The proportion of BAL lymphocytes was
significantly higher in BALn- than in BALn+
patients (p<O.OOl), as shown in Fig. 3. In
6 of 7 (85.7%) BALn+ patients, the pro-
portion of BAL lymphocytes was less than
10%.
Fig. 2. Comparision in FEV1.0% between
type II patients with (BALn+) and
without BAL neutrophilia (BALn-).
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Fig. 3. Comparison in the proportion of
BAL lymphocytes between type II
patients with (BALn+) and without
BAL neutrophilia (BALn-). a;p<
0.001.
Table 2 shows the levels of serum IgG,
IgA and IgM in two asthma groups. The
mean level of serum IgG was slightly lower
in BALn+ patients than the level in those
with BALn-, however, this difference was not
significant. The levels of serumIgA and IgM
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were not different between two asthma
groups.
Table 2. Comparison in levels of serum IgG,
IgA and IgM between type II pa-
tients with (BALn+) and without
BAL neutrophilia (BALn-)
Bronchial asthma is classified into three
fundamental types by clinical pathophysiolog-
ical changes in the airways such as bron-
choconstriction, mucus hypersecretion, and
bronchiolar obstruction ; Ia. simple bron-
choconstriction type, lb. bronchoconstriction
+ hypersecretion type (expectoration, over
100mE/day), and II. bronchiolar obstruction
type 1-5). Moreover, type la is divided into
two subtypes according to expectoration per
day. Ia~l( 0 -49 mE) and Ia-2(50-99mP) 5).
Regardig the proportion of inflammatory
cells, BAL eosinophilia is often found in type
Ib (hypersecretion) 21), and BAL neutrophilia
in type II asthma (bronchiolar obstruction).
The results reveal that pathogenesis of type
II asthma is closely related to increased
number of BAL neutrophils. Futhermore,
BAL neutrophilia related to type II asthma
is often observed in patients with long-term
systemic glucocorticoid therapy, which often
induces decreased number of peripheral lym-
phocytes and decrease in the level of serum
Asthma type
BALn+
BALn-
Serum levels (mg/dl)
IgG IgA IgM
911 ±260 281 ±37 153 ±24
l004±212 294±55 113±75
Discussion
IgG. These lead to suppression of humoral
and cellular immunity 7. 8). It has been sug-
gested from these data that type II asthma
may be caused by suppressed humoral and
cellular immunity, which easily leads to
recurrent respiratory infection.
Despite findings showing a close correlation
between type II asthma and BAL neutro-
philia, our recent studies of asthma demon-
strate that there are some type II asthma
patients without BAL neutrophilia. Thus, this
study was performed to clarify clinical fea-
tures of type II asthma without BAL
neutrophilia (BALn-) by comparing features
of BALn+ patients with same type.
Table 3 shows diffrences in clinical fea-
tures between BALn+ and BALn- patients
with type II asthma. As shown in Table 3,
patint age was higher in BALn- patients than
in those with BALn+. Bronchial hyperrespon-
siveness in both asthma groups was not
different from that in other types of asthma.
FEV 1.0% value, the proportion of BAL
lymphocytes and serum IgG level were mark-
edly decreased in BALn+ patients with type
II asthma compared to those in other types
of asthma. In contrast, decrease in FEV 1.0%
value and serum IgG level were not so re-
markable in BALn- patients with same type,
and the proportion of BAL lymphocytes
showed a tendency to lllcrease, probably due
to aging.
These results suggest that severity of
asthma is in general more mild in BALn-
patients with type II asthma compared to
BALn+ of same type. Further studies are
necessary to analyze the onset mechanisms of
BALn- asthma with type II.
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Table 3. Comparison III clinical features
between BALn+ and BALn- pa-
tients with type IT asthma.
Type II asthma
BALn+ BALn-
Age (years) 50< 60<
Age at onset 40< 35<(years)
Bronchial
--+ --+reactivity
FEV1.0% !! !
BAL !! tlymphocytes
Serum IgG H !
BALn+;type II asthma with BAL neutrophilia,
BALn-;type 1/ asthma without BAL neutrophilia,
*arrows represent the value compared to healthy
subjects.
Conclusion
Type IT (bronchiolar obstruction) asthma
is closely related to BAL neutrophilia. The
present study showed that there are some
type IT asthma patients without BAL
neutrophilia. Clinical features of this type of
asthma were studied comparing to same type
of asthma with BAL neutrophilia.
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BAL液中好中球増加をともなわないⅡ型瑞息に
ついて
谷崎勝朗,御船尚志,光延文裕,保崎泰弘,
芦田耕三,横田 聡,柘野浩史,竹内一昭,
辻 孝夫1)
岡山大学医学部附属病院三朝分院内科,
1)医学部第1内科
細気管支閉塞型 (Ⅱ型)喋息の臨床的特徴が,
BAL液中の好中球頻度との関連のもとに検討さ
れた｡対象13例のうち,7例がBAL液中好中球
増加 (平均好中球頻度 ;53.5%)をともなう症例
(BALn+)で,残りの6例はBAL液中好中球増加
をともなわない (3.5%)症例 (BALn~)であっ
た｡1.平均年齢は,BALn+症例 (55.0才)に比
べ,BALn~症例 (66.0才)でより高い傾向が見ら
れた｡2.メサコリンに対する気道過敏性は,
BALn+症例に比べBALn~症例でやや高い傾向が
見られたが,両者間に有意の差は見られなかった｡
3.FEV1.0%値は,BALnー症例に比べBALn+症
例で有意に低い値を示した (P<0.05)｡4.BA
L液中リンパ球頻度はBALn+症例でBALn~症例に
比べ有意に低い値を示した (P<0.001)｡5.血
清 IgG,IgAおよび IgM値には両者間に有意の
差は見られなかったが,IgG値はBALn+症例でよ
り低い傾向が見られた｡これらの結果より,Ⅱ型
喋息にはBAL液中好中球増加を示す症例と示さ
ない症例の2種類があること,そして前者は免疫
能の低下と,そして後者は加齢とある程度の関連
があることが示唆された｡
キーワード:気管支喋息,細気管支閉塞,BAL
好中球,免疫能低下,加齢
